Oxford BioMedica (OTCMKTS:OXBDF) Downgraded by Zacks Investment Research to Sell

Zacks Investment Research cut shares of Oxford BioMedica (OTCMKTS:OXBDF) from a hold rating to a sell rating in a research note published on Thursday morning, Zacks.com reports.

According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. “

Separately, HC Wainwright reiterated a buy rating and set a $14.50 price objective on shares of Oxford BioMedica in a research report on Wednesday, September 4th.

OTCMKTS OXBDF traded down $0.17 on Thursday, hitting $6.82. 2,361 shares of the stock were exchanged, compared to its average volume of 5,618. Oxford BioMedica has a 52-week low of $6.89 and a 52-week high of $12.20. The company has a market capitalization of $447.94 million, a price-to-earnings ratio of 45.47 and a beta of 0.79. The company’s 50-day moving average price is $8.12 and its two-hundred day moving average price is $8.80.

Oxford BioMedica Company Profile

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

Featured Article: 12b-1 Fees

Get a free copy of the Zacks research report on Oxford BioMedica (OXBDF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit